666831-24-9

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4-[[(methylsulfonyl)oxy]methyl]-, 1,1-dimethylethyl ester, (3R,4R)-
• CAS NO: 666831-24-9
• Molecular Formula: C11H21NO6S
• Molecular Weight: 295.357
• Mol File: 666831-24-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4-[[(methylsulfonyl)oxy]methyl]-, 1,1-dimethylethyl ester, (3R,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4-[[(methylsulfonyl)oxy]methyl]-, 1,1-dimethylethyl ester, (3R,4R)-(666831-24-9)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4-[[(methylsulfonyl)oxy]methyl]-, 1,1-dimethylethyl ester, (3R,4R)-(666831-24-9)

Safety Data

• Hazardous Substances Data: 666831-24-9(Hazardous Substances Data)

Upstream product

• 871086-00-9 (3S,4R)-1-benzyl-4-hydroxy-5-oxopyrrolidine-3-carboxylic acid 

Downstream Products

• 666831-21-6 (3R,4S)-3-acetoxy-1-[(7-benzyloxymethyl-6-tert-butoxy-9-dezahypoxanthin-9-yl)methyl]-4-benzylthiomethylpyrrolidine 
• 666831-20-5 (3R,4S)-1-[(7-benzyloxymethyl-9-dezapurin-9-yl)methyl]-4-benzylthiomethyl-3-hydroxypyrrolidine 
• 666831-22-7 (3R,4S)-3-acetoxy-1-[(7-benzyloxymethyl-9-dezaadenin-9-yl)methyl]-4-benzylthiomethyl-3-hydroxypyrrolidine 
• 666831-27-2 (3R,4S)-1-{[8-aza-9-deaza-8-(tetrahydropyran-2-yl)-6-methoxyhypoxanthin-9-yl]methyl}-3-hydroxy-4-(benzylthiomethyl)pyrrolidine 
• 666831-17-0 (3R,4S)-1-[(7-benzyloxymethyl-6-tert-butoxy-9-deazapurin-9-yl)methyl]-3-hydroxy-4-methylthiomethylpyrrolidine hydrochloride 
• 666831-18-1 (3R,4S)-1-acetoxy-[(7-benzyloxymethyl-6-tert-butoxy-9-deazahypoxanthin-9-yl)methyl]-4-methylthiomethylpyrrolidine 
• 666831-19-2 (3R,4S)-1-[(7-benzyloxymethyl-9-deazaadenin-9-yl)methyl]-3-hydroxy-4-methylthiomethylpyrrolidine 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THERAPY OF PROSTATE CANCER USING DRUG COMBINATIONS TO TARGET POLYAMINE BIOSYNTHESIS AND RELATED PATHWAYS

Provided are compositions and methods for treating prostate conditions. The methods involve administering to an individual in need thereof a composition that contains i) an inhibitor of methionine salvage pathway in prostate of the individual and ii) a polyamine analogue. The methods are for use in individuals who have been diagnosed with, or are suspected of having or at risk for developing androgen sensitive prostate cancer (AS-CaP), or Castration recurrent CaP (CR-CaP), or benign prostate hyperplasia (BPH). The disclosure includes use of inhibitors of methylthioadenosine phosphorylase (MTAP), and a polyamine analog that upregulates polyamine catabolism by increasing spermidine/spermine Nl -acetyl transferase (SAT1) activity, such as methylthio-DADMe-Immucillin (MTDIA), andl),N(11)-bisethylnorspermine (BENSpm), respectively. Pharmaceutical formulations that contain a combination of the inhibitor of the methionine salvage pathway and a polyamine analogue are included, as are kits that contain such agents.